		TOTAL DISCE	SSORE I ORIVI	
Your Man com repo	bined with anti-angioge	nent of MGMT promotenesis and epidermal gro	r unmethylated glioblastoma with PD-1 inhibito wth factor receptor tyrosine kinase inhibitor: a c	
relat part to tr	ted to the content of your n ies whose interests may be	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias.	relationships/activities/interests listed below that are any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment f you are in doubt about whether to list a so.	
	following questions apply t nuscript only.	o the author's relationship	s/activities/interests as they relate to the <u>current</u>	
to th		nsion, you should declare a	efined broadly. For example, if your manuscript pertaill relationships with manufacturers of antihypertensive manuscript.	
	em #1 below, report all sup time frame for disclosure is		in this manuscript without time limit. For all other ite	ms
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initia	planning of the work	
1	All support for the present	XNone		

			none (add rows as	institution)
			needed)	
Ī			Time frame: Since the initial	planning of the work
	1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
l			Time frame: past	36 months
	2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
	3	Royalties or licenses	X_None	

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
U	pending	^	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
	·		
12	Receipt of equipment, materials, drugs, medical	X_None	
	writing, gifts or other		
	services		
13	Other financial or non-	V. Nama	
13		XNone	
	financial interests		
Plea	ise summarize the above co	nflict of interest in th	e following box:
N	lone.		
Plea	ise place an "X" next to the	following statement	to indicate your agreement:
		_	

Date:September. 15 th , 2021 Your Name:Fangfang Du					
Manuscript Title: Treatment of MGMT promoter unmethylated glioblastoma with PD-1 inhibitor combined with anti-angiogenesis and epidermal growth factor receptor tyrosine kinase inhibitor: a case report					
Manuscript number (if known):					
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.					
The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u> .					
The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.					
In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.					

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	X_None	

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
U	pending	^	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
	·		
12	Receipt of equipment, materials, drugs, medical	X_None	
	writing, gifts or other		
	services		
13	Other financial or non-	V. Nama	
13		XNone	
	financial interests		
Plea	ise summarize the above co	nflict of interest in th	e following box:
N	lone.		
Plea	ise place an "X" next to the	following statement	to indicate your agreement:
		_	

Date:Se	ptember. 15 th , 2021
Your Name:	_Yi Ren
-	tle: Treatment of MGMT promoter unmethylated glioblastoma with PD-1 inhibitor ith anti-angiogenesis and epidermal growth factor receptor tyrosine kinase inhibitor: a case
report	
Manuscript nu	umber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
U	pending	^	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
	·		
12	Receipt of equipment, materials, drugs, medical	X_None	
	writing, gifts or other		
	services		
13	Other financial or non-	V. Nama	
13		XNone	
	financial interests		
Plea	ise summarize the above co	nflict of interest in th	e following box:
N	lone.		
Plea	ise place an "X" next to the	following statement	to indicate your agreement:
		_	

	th	
	te:September. 15 th , 2021	
	ur Name:Wei Jiang nnuscript Title: Treatment of MGMT promoter u	unmethylated glioblastoma with PD-1 inhibitor
	mbined with anti-angiogenesis and epidermal growt	·
repo	2 2 2	in factor receptor tyrosine kinase initiation, a cast
	nuscript number (if known):	
relate partie to tra	the interest of transparency, we ask you to disclose all related to the content of your manuscript. "Related" means arties whose interests may be affected by the content of the transparency and does not necessarily indicate a bias. If you do so.	any relation with for-profit or not-for-profit third e manuscript. Disclosure represents a commitment
	e following questions apply to the author's relationships/a inuscript only.	ectivities/interests as they relate to the <u>current</u>
to th	e author's relationships/activities/interests should be <u>defin</u> the epidemiology of hypertension, you should declare all redication, even if that medication is not mentioned in the r	elationships with manufacturers of antihypertensive
	item #1 below, report all support for the work reported in time frame for disclosure is the past 36 months.	this manuscript without time limit. For all other items
	Name all entities with S	pecifications/Comments
	The state of the s	e.g., if payments were made to you or to your
	relationship or indicate in none (add rows as	nstitution)
	needed)	
	Time frame: Since the initial pla	anning of the work

Time frame: past 36 months

All support for the present

manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)

No time limit for this item.

Grants or contracts from

in item #1 above).

Royalties or licenses

any entity (if not indicated

2

3

X__None

X__None

_X__None

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
U	pending	^	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
	·		
12	Receipt of equipment, materials, drugs, medical	X_None	
	writing, gifts or other		
	services		
13	Other financial or non-	V. Nama	
13		XNone	
	financial interests		
Plea	ise summarize the above co	nflict of interest in th	e following box:
N	lone.		
Plea	ise place an "X" next to the	following statement	to indicate your agreement:
		_	